DAJY(002030)2023-12-13 13:56Group 1: Company Overview - Da An Gene has focused on molecular diagnostic technology since its establishment, achieving significant research results and numerous product certifications [1] - The company provides reliable diagnostic solutions for clinical and related fields, with many products widely applied to safeguard public health [1] Group 2: Financial Performance - Da An Gene raised approximately 160 million during its IPO and has not conducted further financing since then [2] - Cumulative cash dividends exceed 4.5 billion since the company went public in 2004 [2] Group 3: Market Strategy - The company aims to strengthen collaborations with hospitals and medical institutions to better understand customer needs and provide more clinical diagnostic solutions [2] - Da An Gene will continue to invest in product research and development to enhance product cost-effectiveness and fulfill social responsibilities [2] Group 4: Competitive Advantage - Da An Gene has developed a complete, domestically leading nucleic acid testing technology supply chain, enabling rapid product development and large-scale production [2] - The company is committed to applying its products and technologies in clinical settings, distinguishing itself from other IVD companies [2]